MDEdge Article about Study of Anakinra for Treatment of COVID-19 Highlights Accompanying Editorial Co-Authored by Dr. Roberto Caricchio

An MDEdge article about the SAVE-MORE study, published in Nature Medicine, also highlighted an accompanying editorial co-authored by Roberto Caricchio, MD, FACR, Chief of the Section of Rheumatology, Professor of Medicine, and Professor of Microbiology and Immunology at the Lewis Katz School of Medicine at Temple University and Director of the Temple Lupus Program at Temple University Hospital. The editorial highlighted the difference between the results of the SAVE-MORE trial and a recent one of canakinumab. The SAVE-MORE trial found that hospitalized patients with COVID-19 at increased risk for respiratory failure showed significant improvement after treatment with anakinra compared with placebo. Anakinra is a recombinant interleukin (IL)-1 receptor antagonist.